Genome Medicine | Article collections

Submit a manuscript Register Contact us Follow us on Twitter

Explore Genome Medicine

Advertisement

Articles

Pharmacogenomics

Edited by: Prof Matthias Schwab

Collection published: 29 November 2012

Last updated: 15 February 2013

Efforts to predict and monitor drug response in individuals and in the population have increased markedly over the past few years, but there is a need for replication, targeted resequencing and functional understanding, and for translation of pharmacogenomics research into the clinic. Genome Medicine presents a series devoted to pharmacogenomics, edited by Matthias Schwab from IKP Stuttgart, Germany, to highlight this important and fast-moving field.

		Review Genes and epigenetic processes as prospective pain targets Megan Crow, Franziska Denk, Stephen B McMahon Genome Medicine 2013, 5:12 (15 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephen McMahon and colleagues review treatments for pain relief, which are often inadequate, and discuss how understanding of the genomic and epigenomic mechanisms might lead to improved drugs.
		Review Pharmacogenomics of adverse drug reactions Ann K Daly Genome Medicine 2013, 5:5 (29 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ann Daly reviews progress in identification of pharmacogenomic risk factors for serious adverse drug reactions, including different approaches used, and prospects for further progress.
		Research MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32 Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, Katherine E Hill, Eleanor Howe, Jeffrey Goldsmith, Kyle Kurek, Antonio R Perez-Atayde, Nancy Francoeur, Jian-Bing Fan, Craig April, Hal Schneider, Mark C Gebhardt, Aedin Culhane, John Quackenbush, Dimitrios Spentzos Genome Medicine 2013, 5:2 (22 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Analysis of miRNA expression in formalin-fixed paraffin-embedded osteosarcoma samples reveals profiles with predictive value for survival, recurrence and chemoresponse.
		Research Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 Anne T Nies, Mikko Niemi, Oliver Burk, Stefan Winter, Ulrich M Zanger, Bruno Stieger, Matthias Schwab, Elke Schaeffeler Genome Medicine 2013, 5:1 (11 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Variations at the SLCO1B1 locus affect hepatic OATP1B1 expression, and the variant c.388A>G strongly alters this expression, which has functional consequences for atorvastatin plasma levels.
		Review Pharmacogenomics of hepatitis C infections: personalizing therapy David R Booth, Golo Ahlenstiel, Jacob George Genome Medicine 2012, 4:99 (26 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary David Booth and colleagues review the pharmacogenetic applications of IL28B genotyping, the only genetic variant currently used diagnostically to predict drug response to hepatitis C virus.
		Research Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling Sandrine Ellero-Simatos, Ewa Szymańska, Ton Rullmann, Wim HA Dokter, Raymond Ramaker, Ruud Berger, Thijs MP van Iersel, Age K Smilde, Thomas Hankemeier, Wynand Alkema Genome Medicine 2012, 4:94 (30 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Metabolomics shows that the off-target effects of the common anti-inflammatory drug prednisolone are dosage and time dependent; this approach is likely to be widely used in drug research.
		Review Pharmacogenomics of chemotherapeutic susceptibility and toxicity Erika L Moen, Lucy A Godley, Wei Zhang, M Eileen Dolan Genome Medicine 2012, 4:90 (30 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Eileen Dolan and colleagues review the contribution of germline genetic variation to chemotherapeutic toxicity and response and discuss the use of lymphoblastoid cell lines in pharmacogenomic studies.
		Editorial Pharmacogenomics: a key component of personalized therapy Matthias Schwab, Elke Schaeffeler Genome Medicine 2012, 4:93 (29 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Matthias Schwab and Elke Schaeffeler reflect on how 'omics' approaches have revolutionized the understanding of disease susceptibility and pathophysiology, leading to potential new therapies.
		Opinion Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action Edward S Dove, Samer A Faraj, Eugene Kolker, Vural Özdemir Genome Medicine 2012, 4:91 (29 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Vural Ozdemir and colleagues discuss the need for narrators, such as philosophers and citizen scientists, to work with scientists to translate pharmacogenomic advances to the clinic.

		Review Genes and epigenetic processes as prospective pain targets Megan Crow, Franziska Denk, Stephen B McMahon Genome Medicine 2013, 5:12 (15 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephen McMahon and colleagues review treatments for pain relief, which are often inadequate, and discuss how understanding of the genomic and epigenomic mechanisms might lead to improved drugs.
		Review Pharmacogenomics of adverse drug reactions Ann K Daly Genome Medicine 2013, 5:5 (29 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ann Daly reviews progress in identification of pharmacogenomic risk factors for serious adverse drug reactions, including different approaches used, and prospects for further progress.
		Research MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32 Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, Katherine E Hill, Eleanor Howe, Jeffrey Goldsmith, Kyle Kurek, Antonio R Perez-Atayde, Nancy Francoeur, Jian-Bing Fan, Craig April, Hal Schneider, Mark C Gebhardt, Aedin Culhane, John Quackenbush, Dimitrios Spentzos Genome Medicine 2013, 5:2 (22 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Analysis of miRNA expression in formalin-fixed paraffin-embedded osteosarcoma samples reveals profiles with predictive value for survival, recurrence and chemoresponse.
		Research Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 Anne T Nies, Mikko Niemi, Oliver Burk, Stefan Winter, Ulrich M Zanger, Bruno Stieger, Matthias Schwab, Elke Schaeffeler Genome Medicine 2013, 5:1 (11 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Variations at the SLCO1B1 locus affect hepatic OATP1B1 expression, and the variant c.388A>G strongly alters this expression, which has functional consequences for atorvastatin plasma levels.
		Review Pharmacogenomics of hepatitis C infections: personalizing therapy David R Booth, Golo Ahlenstiel, Jacob George Genome Medicine 2012, 4:99 (26 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary David Booth and colleagues review the pharmacogenetic applications of IL28B genotyping, the only genetic variant currently used diagnostically to predict drug response to hepatitis C virus.
		Research Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling Sandrine Ellero-Simatos, Ewa Szymańska, Ton Rullmann, Wim HA Dokter, Raymond Ramaker, Ruud Berger, Thijs MP van Iersel, Age K Smilde, Thomas Hankemeier, Wynand Alkema Genome Medicine 2012, 4:94 (30 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Metabolomics shows that the off-target effects of the common anti-inflammatory drug prednisolone are dosage and time dependent; this approach is likely to be widely used in drug research.
		Review Pharmacogenomics of chemotherapeutic susceptibility and toxicity Erika L Moen, Lucy A Godley, Wei Zhang, M Eileen Dolan Genome Medicine 2012, 4:90 (30 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Eileen Dolan and colleagues review the contribution of germline genetic variation to chemotherapeutic toxicity and response and discuss the use of lymphoblastoid cell lines in pharmacogenomic studies.
		Editorial Pharmacogenomics: a key component of personalized therapy Matthias Schwab, Elke Schaeffeler Genome Medicine 2012, 4:93 (29 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Matthias Schwab and Elke Schaeffeler reflect on how 'omics' approaches have revolutionized the understanding of disease susceptibility and pathophysiology, leading to potential new therapies.
		Opinion Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action Edward S Dove, Samer A Faraj, Eugene Kolker, Vural Özdemir Genome Medicine 2012, 4:91 (29 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Vural Ozdemir and colleagues discuss the need for narrators, such as philosophers and citizen scientists, to work with scientists to translate pharmacogenomic advances to the clinic.